Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 7, 2016

View Archived Issues

Lion Biotechnologies submits IND to study LN-145 in cervical, head and neck cancer

Novel biomarker described for congenital disorders of glycosylation

Gilead Sciences discloses PI3K inhibitors

VenatoRx Pharmaceuticals presents beta-lactamase inhibitors

University of Arizona reports melanocorin receptor modulators

Inovio reports results from phase IIb trial of VGX-3100 in cervical intraepithelial neoplasia

NIAID reports results from phase I trial of VRC-01 in people with HIV infection

Vernalis confirms Corvus Pharmaceuticals as licensee for adenosine antagonist program

GSK selects first ImmTAC clinical candidate from Immunocore collaboration

Complix collaborates with Merck & Co. to develop Cell-Penetrating Alphabodies

Oncodesign Biotechnology and Bristol-Myers Squibb form strategic drug discovery collaboration

Gilead terminates phase II study of simtuzumab in idiopathic pulmonary fibrosis

Enterome Bioscience forms gastrointestinal drug discovery collaborations

FDA grants orphan drug designation to anthracycline GPX-150 for soft tissue sarcoma

Dimension Therapeutics' gene therapy DTX-301 granted FDA orphan drug designation

Petra Pharma launched to develop small-molecule drugs for cancer and metabolic disorders

Sensorion cleared to initiate phase I trial of SENS-218 in U.K.

ONT-380 plus T-DM1 shows antitumor activity in MBC

FDA grants fast track designation to seviteronel for metastatic CRPC

FDA awards breakthrough therapy designation to VTS-270 for Niemann-Pick type C1 disease

Sanofi to stop selling MannKind inhaled insulin

Vical's VL-2397 wins FDA orphan drug designation for invasive aspergillosis

OXiGENE's CA4P receives U.S. orphan drug designation for neuroendocrine tumors

Ardelyx reports data for RDX-022 in the treatment of hyperkalemia

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
ASH 2025: Ianalumab data offer break from chronic ITP therapy
BioWorld
Novartis AG’s monoclonal antibody, ianalumab (VAY-736), when added to standard-of-care eltrombopag, extended disease control of primary immune thrombocytopenia...